Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review

Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) approved for ALK-rearranged non-small-cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishiyama, Akihiro, Hattori, Yoshihiro, Takeuchi, Shinji, Tanimoto, Azusa, Satouchi, Miyako, Murayama, Toshinori, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259316/
https://www.ncbi.nlm.nih.gov/pubmed/34803090
http://dx.doi.org/10.2169/internalmedicine.7472-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259316/
https://www.ncbi.nlm.nih.gov/pubmed/34803090
http://dx.doi.org/10.2169/internalmedicine.7472-21

Ejemplares similares